Chronic Lymphocytic Leukaemia: KOL Insight

Maximum Purchase:
1 unit
Publication Date:
September 2016
Adding to cart… The item has been added

Latest Update

Gain new key opinion leader (KOL) insights on the latest events that have the potential to shape the treatment landscape of chronic lymphocytic leukaemia (CLL). Topics covered include several pieces of data presented at The American Society of Hematology’s (ASH) annual meeting in December 2016, including; Phase II data presented for Acerta Pharma/AstraZeneca’s novel inhibitor of bruton’s tyrosine kinase (BTK) acalabrutinib in relapsed/refractory patients who are intolerant to ibrutinib; Phase I data for the combination of TG Therapeutics’ novel PI3 kinase delta inhibitor TGR-1202 in combination with AbbVie/J&J’s Imbruvica (ibrutinib); and the Phase III results published by the German CLL Study Group for Celgene’s Revlimid (lenalidomide) as maintenance in patients with high-risk CLL.

*Latest* Update 2: February 2017
Update 1: November 2016
Original Publication: Sept 2016
*Purchase of this report includes all updates*

This update tackles these key questions

  • How do KOLs view the efficacy and safety of novel BTK inhibitor acalabrutinib in CLL and how does it match up to ibrutinib?
  • What do the experts think about the use of acalabrutinib in ibrutinib-intolerant patients?
  • Will acalabrutinib be able to establish a key role in CLL, and if so, in which treatment settings will it be best positioned?
  • How does the data for the combination of TGR-1202 with ibrutinib sit with KOLs, and what do they think about the combination versus single-agent use?
  • Do KOLs have any toxicity concerns pairing a PI3 kinase inhibitor with a BTK inhibitor?
  • Where will the combination of TGR-1202 and ibrutinib fit in the treatment algorithm and how will the drugs be best utilised?
  • How do KOLs view the Phase III data published for Revlimid maintenance in patients with high-risk CLL and do they envisage it having a future role?
  • Based on the data with Revlimid, will maintenance approaches have a role in CLL?

Update 1

Gain new KOL insights on the latest events that have the potential to shape the treatment landscape of Chronic Lymphocytic Leukaemia (CLL). Topics covered include expert opinions about the recent FDA label expansion of Novartis’ Arzerra (ofatumumab) to the relapsed setting in combination with fludarabine and cyclophosphamide (FC), and the negative EMA decision regarding the use of Arzerra as a maintenance therapy. Experts also discuss the amended design of the Phase III GENUINE study of TG Therapeutics’ ublituximab in combination with Janssen Biotech/AbbVie’s Imbruvica (ibrutinib) and offer further insights on the combination of TG Therapeutics’ TGR-1202 with ublituximab. Following AbbVie’s decision to return full development rights to Infinity Pharmaceuticals for duvelisib, KOLs also weigh in on what this could mean for the drug and its prospects in CLL.

Original Publication: How will established and emerging agents reshape the CLL treatment landscape?

How do key opinion leaders (KOLs) see the future treatment paradigm for chronic lymphocytic leukaemia (CLL) shaping up? Will Gazyva’s/Gazyvaro’s superior efficacy compared to Rituxan/MabThera influence prescribing decisions? How will familiarity, convenience and tolerability influence Imbruvica’s continued uptake? What pipeline therapies do KOLs have their eyes on? Do KOLs predict a significant change in the CLL treatment paradigm in the future? Download sample pages now

Covering 6 marketed drugs and 7 late-stage pipeline therapies, this report reveals candid insights about the CLL landscape from 12 KOLs in North America and Europe. You’ll learn which treatments KOLs consistently choose (and why!), what influences their prescribing of other treatment options, and which pipeline drugs they’re most excited about.

See the Top Takeaways >

“Everything will change. How we will be treating our patients in one year to 18 months will be completely different. Venclexta is coming. Maybe we will be treating all patients in first-line with the BTK inhibitors, and we will be treating all patients in the relapsed/refractory setting with Venclexta.”

Sample of brands covered:

  • Venclexta (venetoclax, AbbVie/Roche)
  • Imbruvica (ibrutinib, AbbVie/Johnson & Johnson)
  • Acalabrutinib (Acerta Pharmaceuticals/AstraZeneca)
  • TGR-1202 (TG Therapeutics)
  • Plus 9 more – download the full list now

Sample of KOLS interviewed

  • Michael J. Keating. Professor of Medicine and Internist, University of Texas MD Anderson Cancer Center, TX.
  • Daniel Catovsky. Emeritus Professor and Fellow, Institute of Cancer Research, London, UK.
  • Emili Montserrat. Professor of Medicine and Director of the Institute of Haematology and Oncology, Hospital Clinic of Barcelona, Spain.
  • Anonymous US KOL
  • Plus 8 more – download the full list now
Back to the top

Top Takeaways

  • Anti-CD20 mAb therapy and chemotherapy dominate at first line – for now. KOLs want to see chemotherapies in first-line replaced by other options. Which agents do they find particularly exciting, and why?
  • While Imbruvica gets high marks for efficacy, its indeterminate treatment schedule is a drawback. What else are KOLs looking for in future treatments? And how could new clinical studies influence thinking?
  • KOLs would like to see more investigation into combination therapy regimens. Find out how experts think combinations could challenge established treatment paradigms.
  • Experts are concerned about the toxicity of CLL treatments. Have FDA safety alerts relegated Zydelig to last-resort status? Will unanswered questions affect the uptake of emerging treatment choices?
  • KOLs provide their views on the use of rituximab biosimilars as treatments for CLL. Should a rituximab biosimilar be approved as a treatment for CLL via indication extrapolation, will it be used? Will cost be the key driver of uptake? Or will Gazyva’s/Gazyvaro’s superior efficacy limit adoption of rituximab biosimilars altogether?
  • Experts concur that the efficacy reported with acalabrutinib to date is impressive. But do they think it could completely replace Imbruvica in CLL? If not, why not?
  • Venclexta is a ‘game-changer’ in CLL. In the context of high enthusiasm for Venclexta, how do KOLs perceive other pipeline agents, in particular PI3K delta or dual inhibitors of P13K delta/gamma?
  • Experts note that Revlimid and CDK inhibitors offer novel mechanisms of action. Are they impressed, and will these options have any potential in CLL?
Back to the top

Money Back Guarantee

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

  • Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date.
  • You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.